Shares of Nuvation Bio Inc. (NYSE:NUVB – Get Free Report) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $13.00.
A number of analysts have recently issued reports on NUVB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. B. Riley Financial restated a “buy” rating on shares of Nuvation Bio in a report on Friday, August 7th. JPMorgan Chase & Co. started coverage on shares of Nuvation Bio in a research report on Tuesday, August 18th. They set an “overweight” rating and a $13.00 price objective on the stock. Citizens Jmp reiterated a “market outperform” rating and issued a $10.00 price objective on shares of Nuvation Bio in a research note on Wednesday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Nuvation Bio in a research note on Tuesday, November 17th.
View Our Latest Research Report on Nuvation Bio
Hedge Funds Weigh In On Nuvation Bio
Nuvation Bio Stock Down 0.3%
Shares of Nuvation Bio stock opened at $3.80 on Thursday. The stock has a 50-day moving average price of $4.87 and a 200 day moving average price of $5.29. The company has a market cap of $1.34 billion, a P/E ratio of -9.50 and a beta of 1.73. The company has a current ratio of 7.45, a quick ratio of 7.30 and a debt-to-equity ratio of 1.23. Nuvation Bio has a 1 year low of $3.71 and a 1 year high of $9.75.
Nuvation Bio (NYSE:NUVB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Nuvation Bio had a negative return on equity of 45.69% and a negative net margin of 67.38%. The firm had revenue of $44.95 million during the quarter, compared to analyst estimates of $34.39 million. As a group, analysts expect that Nuvation Bio will post -0.37 EPS for the current fiscal year.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.
See Also
- Five stocks we like better than Nuvation Bio
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
